Literature DB >> 20086144

Fasting increases tobramycin oral absorption in mice.

Luigina De Leo1, Nicola Di Toro, Giuliana Decorti, Noelia Malusà, Alessandro Ventura, Tarcisio Not.   

Abstract

The pharmacokinetics of the aminoglycoside tobramycin was evaluated after oral administration to fed or fasting (15 h) mice. As expected, under normal feeding conditions, oral absorption was negligible; however, fasting induced a dramatic increase in tobramycin bioavailability. The dual-sugar test with lactulose and l-rhamnose confirmed increased small bowel permeability via the paracellular route in fasting animals. When experiments aimed at increasing the oral bioavailability of hydrophilic compounds are performed, timing of fasting should be extremely accurate.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20086144      PMCID: PMC2849372          DOI: 10.1128/AAC.01172-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Similarity in the linear and non-linear oral absorption of drugs between human and rat.

Authors:  W L Chiou; C Ma; S M Chung; T C Wu; H Y Jeong
Journal:  Int J Clin Pharmacol Ther       Date:  2000-11       Impact factor: 1.366

Review 2.  Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model.

Authors:  Xianhua Cao; Seth T Gibbs; Lanyan Fang; Heather A Miller; Christopher P Landowski; Ho-Chul Shin; Hans Lennernas; Yanqiang Zhong; Gordon L Amidon; Lawrence X Yu; Duxin Sun
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

Review 3.  Alterations in intestinal permeability.

Authors:  M C Arrieta; L Bistritz; J B Meddings
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

4.  Food deprivation and refeeding influence growth, nutrient retention and functional recovery of rats.

Authors:  J J Boza; D Möennoz; J Vuichoud; A R Jarret; D Gaudard-de-Weck; R Fritsché; A Donnet; E J Schiffrin; G Perruisseau; O Ballévre
Journal:  J Nutr       Date:  1999-07       Impact factor: 4.798

Review 5.  Intestinal permeation enhancers.

Authors:  B J Aungst
Journal:  J Pharm Sci       Date:  2000-04       Impact factor: 3.534

6.  Dual sugar gut-permeability testing on blood drop in animal models.

Authors:  Fourogh Katouzian; Daniele Sblattero; Tarcisio Not; Alberto Tommasini; Elena Giusto; Daniela Meiacco; Marco Stebel; Roberto Marzari; Alessio Fasano; Alessandro Ventura
Journal:  Clin Chim Acta       Date:  2005-02       Impact factor: 3.786

7.  Improvement of intestinal peptide absorption by a synthetic bile acid derivative, cholylsarcosine.

Authors:  S Michael; M Thöle; R Dillmann; A Fahr; J Drewe; G Fricker
Journal:  Eur J Pharm Sci       Date:  2000-04       Impact factor: 4.384

8.  Intestinal absorption of octreotide: N-trimethyl chitosan chloride (TMC) ameliorates the permeability and absorption properties of the somatostatin analogue in vitro and in vivo.

Authors:  M Thanou; J C Verhoef; P Marbach; H E Junginger
Journal:  J Pharm Sci       Date:  2000-07       Impact factor: 3.534

9.  Thiolated chitosans: development and in vitro evaluation of an oral tobramycin sulphate delivery system.

Authors:  Juliane Hombach; Herbert Hoyer; Andreas Bernkop-Schnürch
Journal:  Eur J Pharm Sci       Date:  2007-09-08       Impact factor: 4.384

Review 10.  Overview of pediatric short bowel syndrome.

Authors:  Debora Duro; Daniel Kamin; Christopher Duggan
Journal:  J Pediatr Gastroenterol Nutr       Date:  2008-08       Impact factor: 2.839

View more
  5 in total

1.  Administration of substances to laboratory animals: routes of administration and factors to consider.

Authors:  Patricia V Turner; Thea Brabb; Cynthia Pekow; Mary Ann Vasbinder
Journal:  J Am Assoc Lab Anim Sci       Date:  2011-09       Impact factor: 1.232

Review 2.  Nanoparticles for oral delivery: Design, evaluation and state-of-the-art.

Authors:  Abhijit A Date; Justin Hanes; Laura M Ensign
Journal:  J Control Release       Date:  2016-06-09       Impact factor: 9.776

3.  Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour.

Authors:  Serena Deiana; Akihito Watanabe; Yuki Yamasaki; Naoki Amada; Marlene Arthur; Shona Fleming; Hilary Woodcock; Patricia Dorward; Barbara Pigliacampo; Steve Close; Bettina Platt; Gernot Riedel
Journal:  Psychopharmacology (Berl)       Date:  2011-07-28       Impact factor: 4.530

4.  Fusogenic porous silicon nanoparticles as a broad-spectrum immunotherapy against bacterial infections.

Authors:  Byungji Kim; Qinglin Yang; Leslie W Chan; Sangeeta N Bhatia; Erkki Ruoslahti; Michael J Sailor
Journal:  Nanoscale Horiz       Date:  2021-02-18       Impact factor: 10.989

5.  Acute renal failure due to tobramycin intoxication during selective digestive tract decontamination.

Authors:  D Ramnarain; D W de Lange; J Meulenbelt
Journal:  Intensive Care Med       Date:  2011-05-13       Impact factor: 17.440

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.